科兴制药: 股东权益变动触及1%刻度及减持计划完成暨减持股份结果公告

Core Points - The controlling shareholder of Kexing Pharmaceutical, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., has completed a share reduction plan, reducing its stake by 3.00% [1][2][4] - The share reduction was executed through centralized bidding and block trading, with a total of 5,989,200 shares sold [1][4] - Following the reduction, the controlling shareholder's stake decreased from 66.01% to 63.94%, and the total number of shares held is now 125,789,147 [3][4] Shareholder Information - Before the reduction, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. held 131,778,347 shares, representing 66.01% of the company [3] - The reduction plan was first disclosed on June 5, 2025, and the actual reduction occurred between June 26 and July 9, 2025 [4] - The total amount raised from the share reduction was approximately 220.99 million yuan, with share prices ranging from 32.84 to 48.37 yuan per share [4] Impact on Company Structure - The reduction does not trigger a mandatory tender offer and will not lead to changes in the company's controlling shareholder or actual controller [2][5] - The company's governance structure and future operations are not expected to be significantly impacted by this change in shareholding [2][5]